Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708797 | 0.87 | USP30 (0.42) | P2RX7TACR1JAK3USP30GPR119 | |
| SCHEMBL710560 | 0.83 | TACR1 (0.50) | P2RX7TACR1ENPP2NAMPT | |
| SCHEMBL20116386 | 0.82 | SMN1; SMN2 (0.50) | JAK3USP30GPR119NAMPT | |
| SCHEMBL3773434 | 0.81 | P2RX7 (0.48) | P2RX7JAK3JAK2JAK1TYK2 | |
| SCHEMBL712166 | 0.81 | SMN1; SMN2 (0.47) | P2RX7JAK3NAMPT | |
| SCHEMBL710769 | 0.79 | GLS (0.44) | TACR1EPHX2GPR119NAMPT | |
| SCHEMBL3773846 | 0.79 | P2RX7 (0.47) | P2RX7JAK3JAK2JAK1TYK2 | |
| SCHEMBL3776355 | 0.76 | P2RX7 (0.44) | P2RX7JAK3JAK2JAK1TYK2 | |
| SCHEMBL5510202 | 0.75 | JAK2 (0.46) | P2RX7JAK3JAK2JAK1TYK2 | |
| SCHEMBL712501 | 0.75 | P2RX7 (0.43) | P2RX7JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | P2RX7 2105/4885PREP 1417/4885TACR1 467/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | P2RX7 1885/4885PREP 1643/4885TACR1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.